ReviewHuman genomics2023
COVID-19 annual update: a narrative review.
Review in Human genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Longitudinal challenges faced by perinatally-infected young people with HIV in Kenya during the COVID-19 pandemic.AIDS (London, England) · 2026Article
- Pre- and post-COVID-19 pandemic changes in quality of life among medical trainees: impairment and recovery assessed using the WHOQOL questionnaire.BMC medical education · 2026Article
- Modelling severe COVID-19 in TLR3-mutated hiPSCs-derived lung organoids.Cell death discovery · 2025Article
- Mitochondrial haplogroup A2 is associated with increased COVID-19 mortality in an admixed Brazilian population.Scientific reports · 2025Article
- COVID-19 Induces Greater NLRP3 Inflammasome Activation in Obese Patients than Other Chronic Illnesses: A Case-Control Study.International journal of molecular sciences · 2025Article
- Genetic diversity of the immunoglobulin heavy chain locus in cohorts of patients affected with SARS-CoV-2.Human genomics · 2025Article
- An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants.Pathogens (Basel, Switzerland) · 2025Review
- The influence of genetic polymorphisms on cytokine profiles in pediatric COVID-19: a pilot study.Frontiers in pediatrics · 2025Article
- Examining the role of social environment on COVID-19 infections and vaccine uptake among migrants in Japan: Findings from nationwide surveys in 2021 and 2023.Journal of migration and health · 2025Article
- The effect of COVID-19 vaccination on symptomatic infection and related symptoms among preterm-born children aged 3-7 years in China.Scientific reports · 2024Article
- COVID-19 Recovery Time and Its Predictors among Hospitalized Patients in Designated Hospitals in the Madhesh Province of Nepal: A Multicentric Study.Healthcare (Basel, Switzerland) · 2024Article
- A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.Journal of virology · 2024Article
- Alterations in microbiota of patients with COVID-19: implications for therapeutic interventions.MedComm · 2024Review
- Predictive value of D-dimer to albumin ratio for severe illness and mortality in patients with COVID-19.Frontiers in medicine · 2024Article
- Modeling vaccination strategies with limited early COVID-19 vaccine access in low- and middle-income countries: A case study of Thailand.Infectious Disease Modelling · 2023Article
- Development of a Melting-Curve-Based Multiplex Real-Time PCR Assay for the Simultaneous Detection of Viruses Causing Respiratory Infection.Microorganisms · 2023Article
- Liver Involvement during SARS-CoV-2 Infection Is Associated with a Worse Respiratory Outcome in COVID-19 Patients.Viruses · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 6 countries.
Funding
Abstract
Three and a half years after the pandemic outbreak, now that WHO has formally declared that the emergency is over, COVID-19 is still a significant global issue. Here, we focus on recent developments in genetic and genomic research on COVID-19, and we give an outlook on state-of-the-art therapeutical approaches, as the pandemic is gradually transitioning to an endemic situation. The sequencing and characterization of rare alleles in different populations has made it possible to identify numerous genes that affect either susceptibility to COVID-19 or the severity of the disease. These findings provide a beginning to new avenues and pan-ethnic therapeutic approaches, as well as to potential genetic screening protocols. The causative virus, SARS-CoV-2, is still in the spotlight, but novel threatening virus could appear anywhere at any time. Therefore, continued vigilance and further research is warranted. We also note emphatically that to prevent future pandemics and other world-wide health crises, it is imperative to capitalize on what we have learnt from COVID-19: specifically, regarding its origins, the world's response, and insufficient preparedness. This requires unprecedented international collaboration and timely data sharing for the coordination of effective response and the rapid implementation of containment measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.